Cardiac valve replacement developer HighLife Medical has raised $14.3m from investors including medical device maker and existing backer LivaNova.
France-based cardiac installation technology developer HighLife Medical has closed a €12.3m ($14.3m) funding round that included medical device producer LivaNova.
Venture capital firm Sofinnova Partners led the round, which also featured HighLife’s CEO and founder, Georg Börtlein.
Founded in 2010, HighLife has designed a mitral valve replacement system to alleviate a heart condition in which the valve leaks blood toward the lungs. A ring positioned around the damaged valve allows surgeons to insert a replacement without making dangerous incisions into vulnerable…